Updated on:2025-01-09

Nanjing Chiheal Bio Medicine Technology Co., Ltd successfully passed the evaluation for the national Specialized, Refined, Characteristic, and Innovative (Little giants) enterprise, thanks to its comprehensive corporate strength, and was granted the title of……

Updated on:2023-07-16

Marbaloxavir (Xofluza) is a Cap-dependent endonuclease inhibitor and the only approved single-dose oral medication for the treatment of influenza. It is also the first antiviral flu drug with a novel mechanism of action to be approved by the U.S. FDA in nearly 20 years. It has been approved in multiple countries, including the United States, Japan, and China.

Updated on:2023-07-16

Chiheal Pharma Factory two products, ornidazole injection (specifications: 3ml:0.5g, 6ml:1.0g) and tranexamic acid injection (specification: 2.5ml:0.25g), have lived up to expectations, achieving a remarkable success by both being selected in the eighth batch of the national centralized procurement bidding list! The success of these two products is a result of the careful preparation and strategic planning by the group’s leadership, culminating in this excellent achievement!

Updated on:2023-05-16

Since its establishment in 2018, Chiheal Pharmaceutical Group has adhered to the principles of being clinically demand-driven, innovation-focused, and customer-centered. Through high-quality, efficient, and cost-effective research and development services, the company has helped clients seize timely opportunities related to consistency evaluation, MAH new policies, and centralized procurement. This has empowered the development and growth of partner enterprises, enabling all parties to achieve r

Updated on:2022-09-27

On September 9, 2022, during the 2nd China Pharmaceutical Distribution and Trade Conference and the 2nd World Pharmaceutical Retail Conference, the Xingchen Capital Forum, sponsored by Hongjitang, was successfully held.

Updated on:2022-07-19

Recently, Dr. Zhang Zhefeng, Chairman of Chiheal Group, led a delegation of senior executives to visit the Guangdong Biopharmaceutical Innovation Association for learning and exchange. The delegation also held discussions with entrepreneurs from Guangzhou and Shenzhen. Zhu Shaoxuan, Executive President of the Association, warmly received the group and presided over the exchange meeting.

Updated on:2022-06-27

On June 24, 2022, Liu Zhongliang, Executive President and Secretary-General of the China Pharmaceutical Materials Association, along with Dai Dexiong, Vice President of Zhejiang Weikang Pharmaceutical Co., Ltd., and Assistant Director Hua Jie, visited Zhihe Pharmaceutical for inspection and exchange. Dr. Zhang Zhefeng, Chairman of Chihealbio, warmly welcomed the delegation along with the company’s senior management team.

Updated on:2022-05-18

Empowering with Intelligence, Shaping the Future through Data. The Mufu Innovation Zone Investment Promotion and Signing Conference was successfully held on May 12 in Ningqi District. The event utilized a combination of online and offline formats to showcase the top-level design of the smart city, application scenarios, and the investment environment of the Mufu Innovation Zone. Participants included Shan Zhiguang, Director of the Informatization and Industrial Development Department of the Nat

Updated on:2022-03-29

On March 28, 2022, Nanjing Chiheal Pharmaceutical Technology Co., Ltd. (hereinafter referred to as \"Chiheal Pharmaceutical\") and Zhejiang Weikang Pharmaceutical Co., Ltd. (hereinafter referred to as \"Weikang Pharmaceutical\") signed a strategic cooperation agreement. The two parties will establish a strategic partnership, strengthening collaboration in areas such as pharmaceutical project selection, joint development, and contracted R&D, aiming to achieve mutual succes